Drug Safety Monitoring Center, Seoul National University Hospital, Seoul, Korea.
Department of Immunology and Rheumatology, Nepean Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
J Allergy Clin Immunol Pract. 2021 Feb;9(2):929-936.e7. doi: 10.1016/j.jaip.2020.09.011. Epub 2020 Sep 19.
Because severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) rarely occur, clinical data based on large-scale studies are still lacking.
To provide information on culprit drugs and clinical characteristics, including morbidity and mortality of SCARs based on a nationwide registry.
SCAR cases that occurred from 2010 to 2015 were recruited to the Korean SCAR registry from 34 tertiary referral hospitals. Demographics, causative drugs, causality, and clinical outcomes were collected by reviewing the medical record.
A total of 745 SCAR cases (384 SJS/TEN cases and 361 DRESS cases) due to 149 drugs were registered. The main causative drugs were allopurinol (14.0%), carbamazepine (9.5%), vancomycin (4.7%), and antituberculous agents (6.3%). A strong preference for SJS/TEN was observed in carbonic anhydrase inhibitors (100%), nonsteroidal anti-inflammatory drugs (84%), and acetaminophen (83%), whereas dapsone (100%), antituberculous agents (81%), and glycopeptide antibacterials (78%) were more likely to cause DRESS. The mortality rate was 6.6% (SJS/TEN 8.9% and DRESS 4.2%). The median time to death was 19 days and 29 days in SJS/TEN and DRESS respectively, and 89.8% of deaths occurred within 60 days after the onset of the skin symptoms.
Allopurinol, carbamazepine, vancomycin, and antituberculous agents were the leading causes of SCARs in Korea. Some drugs preferentially caused a specific phenotype. The mortality rate of SCARs was 6.6%, and most of the deaths occurred within 2 months.
由于严重的皮肤不良反应(SCARs),如史蒂文斯-约翰逊综合征(SJS)、中毒性表皮坏死松解症(TEN)和药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)很少发生,因此仍缺乏基于大规模研究的临床数据。
通过全国性登记处,提供有关 SCAR 致病药物和临床特征的信息,包括发病率和死亡率。
从 34 家三级转诊医院招募了 2010 年至 2015 年发生的 SCAR 病例到韩国 SCAR 登记处。通过审查病历收集人口统计学、致病药物、因果关系和临床结局。
共登记了 745 例 SCAR 病例(384 例 SJS/TEN 病例和 361 例 DRESS 病例),涉及 149 种药物。主要致病药物分别为别嘌醇(14.0%)、卡马西平(9.5%)、万古霉素(4.7%)和抗结核药物(6.3%)。碳酸酐酶抑制剂(100%)、非甾体抗炎药(84%)和对乙酰氨基酚(83%)更倾向于引起 SJS/TEN,而磺胺(100%)、抗结核药物(81%)和糖肽类抗生素(78%)更可能引起 DRESS。死亡率为 6.6%(SJS/TEN 为 8.9%,DRESS 为 4.2%)。SJS/TEN 和 DRESS 的中位死亡时间分别为 19 天和 29 天,89.8%的死亡发生在皮肤症状出现后 60 天内。
别嘌醇、卡马西平、万古霉素和抗结核药物是韩国 SCAR 的主要原因。一些药物优先导致特定的表型。SCAR 的死亡率为 6.6%,大多数死亡发生在 2 个月内。